Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

Open in Screener

MTSR

Metsera Inc

Feb 11 • 04:00PM ET

30.76

Dollar change +0.68
Percentage change 2.26	%

Healthcare • Biotechnology • USA • NASD

Held by: ONEQ BMED

Index	-	P/E	-	EPS (ttm)	-	Insider Own	38.63%	Shs Outstand	103.04M	Perf Week	9.82%
Market Cap	3.16B	Forward P/E	-	EPS next Y	-	Insider Trans	15.14%	Shs Float	63.23M	Perf Month	-
Income	-	PEG	-	EPS next Q	-	Inst Own	1.80%	Short Float	-	Perf Quarter	-
Sales	-	P/S	-	EPS this Y	-	Inst Trans	29.10%	Short Ratio	-	Perf Half Y	-
Book/sh	-0.44	P/B	-	EPS next Y	-	ROA	-	Short Interest	-	Perf Year	-
Cash/sh	0.73	P/C	42.04	EPS next 5Y	-	ROE	-	52W Range	25.06 - 31.64	Perf YTD	16.08%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-2.78%	Beta	-
Dividend TTM	-	Quick Ratio	3.81	Sales past 5Y	0.00%	Gross Margin	-	52W Low	22.75%	ATR (14)	2.39
Dividend Ex-Date	-	Current Ratio	3.81	EPS Y/Y TTM	-	Oper. Margin	-	RSI (14)	-	Volatility	6.34% -
Employees	-	Debt/Eq	0.01	Sales Y/Y TTM	-	Profit Margin	-	Recom	-	Target Price	-
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	-	Payout	-	Rel Volume	0.12	Prev Close	30.08
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	-	Avg Volume	1.38M	Price	30.76
SMA20	6.33%	SMA50	6.33%	SMA200	6.33%	Trades		Volume	166,935	Change	2.26%

Feb-05-25 04:01PM	Metsera Announces Closing of Initial Public Offering and Full Exercise and Closing of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Jan-30-25 08:13PM	Drugmakers Metsera and Maze Raise Combined $415 Million in IPOs (Bloomberg)
06:53PM	Metsera Announces Pricing of Initial Public Offering (GlobeNewswire)
02:57PM	Metsera, Maze secure combined $415 million in IPOs (BioPharma Dive)

Metsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o. The company was founded by Clive A. Meanwell in 2022 and is headquartered in New York.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Burow Kristina	Director	Feb 03 '25	Buy	18.00	2,222,222	39,999,996	18,503,128	Feb 03 07:15 PM
BERNS PAUL L	Director	Feb 03 '25	Buy	18.00	789,998	14,219,964	8,313,680	Feb 03 07:04 PM
ARCH Venture Partners XII, LLC	10% Owner	Feb 03 '25	Buy	18.00	2,222,222	39,999,996	18,503,128	Feb 03 07:01 PM

Open in Screener

PRME

Prime Medicine Inc

Feb 11 • 04:00PM ET

2.28

Dollar change -0.14
Percentage change -5.79	%

Healthcare • Biotechnology • USA • NASD

PRME Prime Medicine Inc daily Stock Chart

Peers: CRSP NTLA EDIT BEAM ALLO VERV DNLI IGMS PSTX SANA

| Held by: VTI ARKG ARKK IWM VXF IWO IBB VTWO SCHA VHT

Index	RUT	P/E	-	EPS (ttm)	-2.01	Insider Own	61.20%	Shs Outstand	131.16M	Perf Week	-11.97%
Market Cap	299.05M	Forward P/E	-	EPS next Y	-1.22	Insider Trans	0.00%	Shs Float	50.89M	Perf Month	-22.45%
Income	-219.25M	PEG	-	EPS next Q	-0.38	Inst Own	32.79%	Short Float	33.82%	Perf Quarter	-44.39%
Sales	0.80M	P/S	373.81	EPS this Y	26.60%	Inst Trans	0.03%	Short Ratio	15.27	Perf Half Y	-45.65%
Book/sh	1.44	P/B	1.58	EPS next Y	24.04%	ROA	-76.67%	Short Interest	17.21M	Perf Year	-66.12%
Cash/sh	1.34	P/C	1.70	EPS next 5Y	20.17%	ROE	-114.35%	52W Range	2.37 - 9.77	Perf YTD	-21.92%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-193.88%	ROI	-96.90%	52W High	-76.66%	Beta	1.88
Dividend TTM	-	Quick Ratio	6.50	Sales past 5Y	-25.00%	Gross Margin	-607.25%	52W Low	-3.80%	ATR (14)	0.21
Dividend Ex-Date	Sep 10, 2019	Current Ratio	6.50	EPS Y/Y TTM	-7.14%	Oper. Margin	-26598.50%	RSI (14)	31.68	Volatility	7.20% 7.47%
Employees	234	Debt/Eq	0.22	Sales Y/Y TTM	-	Profit Margin	-27406.12%	Recom	1.20	Target Price	14.12
Option/Short	Yes / Yes	LT Debt/Eq	0.19	EPS Q/Q	20.58%	Payout	-	Rel Volume	1.26	Prev Close	2.42
Sales Surprise	-97.12%	EPS Surprise	-14.20%	Sales Q/Q	-	Earnings	Nov 12 AMC	Avg Volume	1.13M	Price	2.28
SMA20	-18.09%	SMA50	-22.38%	SMA200	-48.26%	Trades		Volume	1,416,419	Change	-5.79%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-10-24	Initiated	JMP Securities	Mkt Outperform	$10
May-20-24	Initiated	H.C. Wainwright	Buy	$10
May-16-24	Upgrade	Citigroup	Neutral → Buy	$10
Apr-22-24	Initiated	Chardan Capital Markets	Buy	$17
Apr-08-24	Initiated	TD Cowen	Buy
Apr-03-24	Initiated	Wedbush	Outperform	$12
Jan-16-24	Downgrade	Stifel	Buy → Hold	$18 → $9
Dec-08-23	Initiated	Citigroup	Neutral	$10
Oct-09-23	Initiated	BMO Capital Markets	Outperform	$19
Jul-31-23	Initiated	Guggenheim	Buy	$24
Apr-18-23	Initiated	Stifel	Buy	$18
Nov-14-22	Initiated	Morgan Stanley	Equal-Weight	$23
Nov-14-22	Initiated	JP Morgan	Overweight	$27
Nov-14-22	Initiated	Jefferies	Buy	$25
Nov-14-22	Initiated	Goldman	Neutral	$22

Show Previous Ratings

Jan-07-25 08:00AM	Prime Medicine to Present at 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-31-24 01:00PM	Is Prime Medicine (PRME) Among the Top CRISPR Stocks to Invest In? (Insider Monkey) +5.04%
Dec-30-24 02:46PM	Why Prime Medicine (PRME) Is One of the Best Biotech Penny Stocks to Invest in Now? (Insider Monkey)
Dec-29-24 06:25AM	Prime Medicine, Inc. (PRME): Is This Gene Therapy Stock a Good Buy Right Now? (Insider Monkey)
Nov-12-24 04:00PM	Prime Medicine Reports Third Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire) -8.33%
04:00PM	Loading…
Nov-06-24 04:00PM	Prime Medicine to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-28-24 10:00AM	12 High-Growth Stocks That Could Deliver Parabolic Returns (Motley Fool)
Oct-24-24 08:00AM	Prime Medicine Presents In Vivo Proof-of-Concept Data Highlighting Interim Preclinical Advances in its Wilson's Disease Program and the Broad Potential of its Universal Liver-Targeted LNP at ESGCT 31st Annual Congress (GlobeNewswire) +5.26%
Oct-16-24 09:45AM	Why I Keep Buying These 14 Incredible Growth Stocks (Motley Fool) +5.04%
Oct-15-24 08:00AM	Prime Medicine to Highlight New Preclinical Data, Including In Vivo Data in Wilson's Disease, at Upcoming Scientific Meetings (GlobeNewswire)
Oct-01-24 09:33AM	BMS and Prime ink potential $3.5bn deal to develop T cell therapies (Pharmaceutical Technology) -10.85%
Sep-30-24 06:08PM	Why Prime Medicine Stock Soared Nearly 12% Higher on Monday (Motley Fool) +11.85%
08:38AM	Prime Medicine Inks Cell Therapy Pact With Bristol Myers Squibb Worth Over $3.5B, Streamlines Pipeline (Benzinga)
07:01AM	Prime Medicine Unveils Strategically Focused Pipeline (GlobeNewswire)
07:00AM	Prime Medicine Announces Strategic Research Collaboration and License Agreement with Bristol Myers Squibb to Develop and Commercialize Multiple Prime Edited Ex Vivo T-Cell Therapies (GlobeNewswire)
06:30AM	Loading…
06:30AM	Prime to narrow gene editing research as it strikes deal with Bristol Myers (BioPharma Dive)
Aug-28-24 08:15AM	2 Growth Stocks That Could Make You Richer (Motley Fool)
08:00AM	Prime Medicine to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-08-24 08:00AM	Prime Medicine Reports Second Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Jul-31-24 01:53PM	Prime Medicine (PRME) Stock: Buy or Sell Before Q2 Earnings? (Zacks)
Jul-19-24 10:00AM	Prime Medicine (PRME) Gains 16.4% in 3 Months: Buy Now or Wait? (Zacks)
Jul-08-24 05:44PM	Prime Medicine, Inc. (PRME): Why Do Analysts Love This Shorted Stock Right Now? (Insider Monkey)
12:30PM	10 Most Shorted Stocks That Are Loved by Analysts (Insider Monkey)
May-30-24 09:55AM	Wall Street Analysts Believe Prime Medicine, Inc. (PRME) Could Rally 120.95%: Here's is How to Trade (Zacks)
08:00AM	Prime Medicine to Present at Upcoming Investor Conferences (GlobeNewswire)
May-29-24 06:30AM	If You Can Only Buy One Biotech Stock in May, It Better Be One of These 3 Names (InvestorPlace)
May-25-24 04:10AM	Here Are the 2 Growth Stocks Google's Parent Company Just Added to Its $7 Billion Portfolio (Motley Fool)
May-20-24 09:32PM	Cathie Wood Pulls the Trigger on These 2 Strong Buy Stocks (TipRanks) +6.36% +6.64%
09:33AM	HC Wainwright Starts Coverage on Prime Medicine With Buy Rating, $10 Price Target (MT Newswires)
May-17-24 06:27AM	Wall Street Favorites: 3 Cathie Wood Stocks With Strong Buy Ratings for May 2024 (InvestorPlace)
06:15AM	Loading…
06:15AM	Wall Street Favorites: 3 Biotech Stocks with Strong Buy Ratings for May 2024 (InvestorPlace)
May-16-24 07:14AM	Citigroup Upgrades Prime Medicine at Buy From Neutral With $10 Price Target (MT Newswires)
May-14-24 09:55AM	Does Prime Medicine, Inc. (PRME) Have the Potential to Rally 133.64% as Wall Street Analysts Expect? (Zacks)
May-13-24 11:12AM	JPMorgan Adjusts Price Target on Prime Medicine to $15 From $16, Keeps Overweight Rating (MT Newswires) +14.44%
08:00AM	Prime Medicine to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ (GlobeNewswire)
May-12-24 03:00AM	Alphabet Bought Up Two Slumping Stocks (Barrons.com)
May-10-24 02:23PM	Prime Medicine Inc (PRME) Q1 2024 Earnings: Navigates Through Challenges with Strategic Developments (GuruFocus.com)
01:53PM	PRME Stock Earnings: Prime Medicine Beats EPS for Q1 2024 (InvestorPlace)
08:00AM	Prime Medicine Reports First Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
May-08-24 08:00AM	Prime Medicine Presents Preclinical Data Demonstrating Ability of PM359 to Efficiently, Reproducibly and Durably Correct Causative Mutation of Chronic Granulomatous Disease (CGD) (GlobeNewswire)
May-03-24 12:00PM	What Makes Prime Medicine, Inc. (PRME) a New Buy Stock (Zacks)
May-01-24 08:00AM	Prime Medicine to Participate in the 27th Annual Milken Institute Global Conference (GlobeNewswire) +7.11%
Apr-30-24 06:01AM	Prime Medicine gets green light for trials of first-ever prime editing drug (Clinical Trials Arena)
Apr-29-24 10:12AM	Prime Medicine Shares Jump After Application for Chronic Granulomatous Disease Treatment Gets FDA Clearance (MT Newswires) +9.83%
07:35AM	Prime gets FDA green light to begin first trial test of prime editing (BioPharma Dive)
07:33AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace)
07:00AM	Prime Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for PM359 for the Treatment of Chronic Granulomatous Disease (CGD) (GlobeNewswire)
Apr-23-24 08:00AM	Prime Medicine to Present Preclinical Data Demonstrating Broad Potential of Prime Editing Technology at Upcoming Scientific Meetings (GlobeNewswire)
Mar-27-24 08:45AM	2 Magnificent Growth Stocks With Room to Run (Motley Fool)
Mar-14-24 02:44PM	Short-Squeeze Roulette: 3 Stocks That Could Leave Bears Begging (InvestorPlace) -13.18%
Mar-01-24 02:00PM	Cathie Wood Just Bought These 3 Biotech Stocks. Should You Buy, Too? (InvestorPlace)
08:00AM	Prime Medicine Reports Full Year 2023 Financial Results and Provides Business Updates (GlobeNewswire)
Feb-29-24 03:02AM	14 Stocks With Heavy Insider Buying In 2024 (Insider Monkey) -5.99%
Feb-28-24 08:00AM	Prime Medicine to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-20-24 04:01PM	Prime Medicine Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares (GlobeNewswire) -5.08% +5.73%
Feb-14-24 11:50PM	Prime Medicine Announces Pricing of Upsized Public Offering (GlobeNewswire) +13.62%
04:05PM	Prime Medicine Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Feb-01-24 08:00AM	Prime Medicine to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference (GlobeNewswire) +5.67%
Jan-25-24 08:00AM	Prime Medicine Receives Up to $15 Million from Cystic Fibrosis Foundation to Advance Hotspot and PASSIGE Prime Editors for Cystic Fibrosis (GlobeNewswire)
Jan-09-24 06:21PM	Wall Street Analysts Predict an 111.38% Upside in Prime Medicine, Inc. (PRME): Here's What You Should Know (Zacks)
Jan-05-24 05:00PM	Prime Medicine and Myeloid Therapeutics Announce Settlement of Pending Disputes (PR Newswire)
08:00AM	Prime Medicine Appoints Allan Reine, M.D., as Chief Financial Officer (GlobeNewswire)
Jan-02-24 08:00AM	Prime Medicine to Present at 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-19-23 10:30AM	Better Growth Stock: Archer Aviation or Prime Medicine? (Motley Fool) +6.73%
Nov-30-23 07:45AM	1 Cathie Wood Stock That Could Deliver Life-Changing Returns in 10 Years (Motley Fool)
Nov-08-23 08:00AM	Prime Medicine to Present at Upcoming Investor Conferences (GlobeNewswire) -9.75%
Nov-03-23 04:01PM	Prime Medicine Reports Third Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire) +17.65%
Oct-30-23 03:46PM	Top 20 Genomics Companies in the World (Insider Monkey)
Oct-27-23 06:00AM	Prime Medicine Presents First-ever Prime Editing Data in Non-human Primates Demonstrating Highly Efficient Ability of Prime Editors to Precisely Correct Disease-causing Mutation of GSD1b (GlobeNewswire) -6.60%
Oct-24-23 07:30AM	Prime Medicine Presents First In Vivo Proof-of-Concept Prime Editing Data Demonstrating Ability of Prime Editors to Treat Ophthalmological Diseases (GlobeNewswire)
05:04AM	The Bull Market Can Continue to Roll On; BMOs Brian Belski Predicts Further Gains for Stocks Here Are 3 Names to Play That Bullish Sentiment (TipRanks)
Oct-23-23 02:50AM	7 Biotech Stocks to Get In Now Before Investors Catch On (InvestorPlace)
Oct-17-23 08:00AM	Prime Medicine to Highlight Positive Preclinical Developments Across Prime Editing Pipeline and Platform at Upcoming Industry Conferences (GlobeNewswire) +10.00%
Oct-09-23 09:33AM	Oracle upgraded, Spotify downgraded: Wall Street's top analyst calls (The Fly)
Sep-19-23 08:00AM	Prime Medicine to Present at Upcoming Investor Conferences (GlobeNewswire)
Aug-31-23 08:00AM	Prime Medicine to Present at Upcoming Investor Conferences (GlobeNewswire)
Aug-07-23 04:01PM	Prime Medicine Reports Second Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire) -8.66%
Jul-25-23 07:45AM	2 Cathie Wood Stocks That Could Be Hidden Gems (Motley Fool)
Jun-29-23 08:46AM	We're Hopeful That Prime Medicine (NASDAQ:PRME) Will Use Its Cash Wisely (Simply Wall St.)
Jun-22-23 08:00AM	Prime Medicine and Cimeio Therapeutics Announce Research Collaboration to Develop Prime Edited Shielded-Cell & Immunotherapy Pairs for Genetic Diseases, Acute Myeloid Leukemia and Myelodysplastic Syndrome (GlobeNewswire)
Jun-02-23 10:15AM	Cathie Wood Goes Bargain-Hunting: 3 Stocks She Just Bought (Motley Fool) +9.15%
May-31-23 08:00AM	Prime Medicine to Present at Investor Conferences in June (GlobeNewswire)
May-26-23 09:45AM	Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought (Motley Fool)
May-17-23 04:05PM	Prime Medicine to Present at Virtual Investor Conferences in May (GlobeNewswire)
06:00AM	Prime Medicine to Present New Preclinical Data Highlighting Broad Potential of Prime Editing Technology at ASGCT 26th Annual Meeting (GlobeNewswire)
May-11-23 08:00AM	Prime Medicine Reports First Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire) -10.61%
Mar-27-23 08:00AM	Prime Medicine to Present at Guggenheim Healthcare Talks Genomic Medicines and Rare Disease Days (GlobeNewswire) +5.89%
Mar-09-23 08:00AM	Prime Medicine Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update (GlobeNewswire)
Feb-27-23 08:00AM	Prime Medicine to Present at Cowen 43rd Annual Health Care Conference (GlobeNewswire)
Jan-20-23 05:56AM	We Think Prime Medicine (NASDAQ:PRME) Needs To Drive Business Growth Carefully (Simply Wall St.)
Jan-09-23 07:00AM	Prime Medicine Announces Recent Progress and Highlights 2023 Strategic Priorities (GlobeNewswire)
Jan-03-23 08:00AM	Prime Medicine to Present at 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -5.60%
Nov-01-22 04:13PM	After Prime Medicine, What's the Next Gene Editing IPO? (TheStreet.com) +12.22%
Oct-24-22 05:30PM	Prime Medicine Announces Closing of Upsized Initial Public Offering (GlobeNewswire) +5.59%
Oct-20-22 12:45PM	UPDATE 1-Biotech firm Prime Medicine valued at $1.8 bln in strong debut (Reuters)
Oct-19-22 09:47PM	Prime Medicine Announces Pricing of Upsized Initial Public Offering (Business Wire)

Prime Medicine, Inc. is a biotechnology company, which engages in developing one-time curative genetic therapies. The company was founded by David R. Liu on September 13, 2019 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
NELSEN ROBERT	Director	Feb 15 '24	Buy	6.25	3,200,000	20,000,000	3,200,000	Feb 20 05:41 PM
ARCH Venture Partners XII, LLC	10% Owner	Feb 15 '24	Buy	6.25	3,200,000	20,000,000	3,200,000	Feb 20 05:38 PM
ARCH Venture Partners X, LLC	10% Owner	Feb 15 '24	Buy	6.25	3,200,000	20,000,000	3,200,000	Feb 20 05:37 PM

Dollar change -0.11
Percentage change -6.18	%

NMRA Neumora Therapeutics Inc daily Stock Chart

Peers: BIIB VRTX NBIX AXSM ACAD SAGE ALKS BHVN PRTA AVXL

| Held by: VTI VXF VTWO IWM VHT IWO VTWG SCHA IBB XPH

Index	RUT	P/E	-	EPS (ttm)	-1.85	Insider Own	65.85%	Shs Outstand	160.48M	Perf Week	-12.57%
Market Cap	269.81M	Forward P/E	-	EPS next Y	-1.61	Insider Trans	-0.20%	Shs Float	55.17M	Perf Month	-24.43%
Income	-293.70M	PEG	-	EPS next Q	-0.44	Inst Own	30.22%	Short Float	19.99%	Perf Quarter	-87.17%
Sales	0.00M	P/S	-	EPS this Y	55.94%	Inst Trans	5.39%	Short Ratio	3.61	Perf Half Y	-85.17%
Book/sh	2.00	P/B	0.84	EPS next Y	-0.85%	ROA	-65.46%	Short Interest	11.03M	Perf Year	-90.43%
Cash/sh	2.12	P/C	0.79	EPS next 5Y	25.35%	ROE	-70.48%	52W Range	1.71 - 21.00	Perf YTD	-84.25%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-91.57%	52W High	-92.05%	Beta	2.49
Dividend TTM	-	Quick Ratio	10.98	Sales past 5Y	0.00%	Gross Margin	-	52W Low	-2.34%	ATR (14)	0.33
Dividend Ex-Date	-	Current Ratio	10.98	EPS Y/Y TTM	-80.83%	Oper. Margin	-	RSI (14)	20.52	Volatility	6.19% 7.75%
Employees	124	Debt/Eq	0.01	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.44	Target Price	14.99
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	-30.90%	Payout	-	Rel Volume	0.55	Prev Close	1.78
Sales Surprise	-	EPS Surprise	-15.24%	Sales Q/Q	-	Earnings	Nov 12 BMO	Avg Volume	3.06M	Price	1.67
SMA20	-16.29%	SMA50	-71.84%	SMA200	-83.28%	Trades		Volume	1,668,924	Change	-6.18%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-02-25	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$29 → $4
Nov-05-24	Downgrade	JP Morgan	Overweight → Neutral	$18 → $15
Oct-01-24	Initiated	H.C. Wainwright	Buy	$30
Jul-22-24	Initiated	Needham	Buy	$23
Jul-08-24	Initiated	Mizuho	Outperform	$20
Dec-12-23	Initiated	Deutsche Bank	Hold	$13
Oct-10-23	Initiated	William Blair	Outperform	$26
Oct-10-23	Initiated	Stifel	Buy	$26
Oct-10-23	Initiated	RBC Capital Mkts	Outperform	$24
Oct-10-23	Initiated	JP Morgan	Overweight	$21
Oct-10-23	Initiated	Guggenheim	Buy	$22
Oct-10-23	Initiated	BofA Securities	Buy	$18

Show Previous Ratings

Feb-11-25 05:45AM	Investors in Neumora Therapeutics, Inc. Should Contact Levi & Korsinsky Before April 7, 2025 to Discuss Your Rights - NMRA (PR Newswire) -6.18%
Jan-04-25 08:00AM	Neumora shares look oversold after 80% drop, says Mizuho (TipRanks)
Jan-03-25 07:20AM	Neumora Therapeutics navacaprant did not meet primary endpoint in depression (TipRanks) +10.15%
Jan-02-25 05:07PM	Results are in for a new depression drug trial, and they're cratering this stock (Quartz) -81.42%
04:22PM	Neumora Therapeutics Stock Crashes 81% After Depression Drug Flops (Investor's Business Daily)
01:28PM	Loading…
01:28PM	Neumora Nosedives 80% At Pre-Market on Failed Depression Drug Trial (Insider Monkey)
01:07PM	Neumora shares sink following Phase III flop in MDD (Pharmaceutical Technology)
12:00PM	Top Stock Movers Now: Uber, Unity Software, Tesla, and More (Investopedia)
10:47AM	Neumora Therapeutics Stock Tanks as Its Depression Drug Misses Goals (Investopedia)
09:59AM	Stock in Biotech Neumora Plunges 80% as Depression Drug Fails (Barrons.com)
09:54AM	Neumora Plunges After Major Depression Drug Fails in Study (Bloomberg)
08:30AM	Neumora Therapeutics Depression Drug Fails In First Of Three Pivotal Phase 3 Trials (Benzinga)
07:00AM	Neumora Therapeutics Reports Data from KOASTAL-1 Study of Navacaprant in Major Depressive Disorder (GlobeNewswire)
Nov-19-24 08:53AM	Neumora Therapeutics, Inc. (NMRA): This Small-Cap Stock Is Ready To Explode (Insider Monkey)
Nov-12-24 07:00AM	Neumora Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire) -17.08%
07:00AM	Loading…
Nov-06-24 07:00AM	Neumora Therapeutics to Participate in Upcoming Conferences in November (GlobeNewswire) +6.72%
Oct-29-24 07:00AM	Neumora Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024 (GlobeNewswire)
Aug-14-24 07:00AM	Neumora Therapeutics to Host Key Opinion Leader Roundtable to Discuss the Potential of Navacaprant in Neuropsychiatric Disorders (GlobeNewswire)
Aug-06-24 01:54PM	NMRA Stock Earnings: Neumora Therapeutics Meets EPS for Q2 2024 (InvestorPlace)
07:00AM	Neumora Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Jul-01-24 01:00AM	10 clinical trials to watch in the second half of 2024 (BioPharma Dive)
Jun-20-24 07:00AM	Neumora Therapeutics Announces Initiation of Phase 1b Study of NMRA-511 for Treatment of Alzheimer's Disease Agitation (GlobeNewswire)
May-14-24 08:52AM	Neumora Therapeutics Begins Phase 2 Study of Navacaprant in Bipolar Depression (MT Newswires) +6.92%
07:00AM	Neumora Therapeutics Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression (GlobeNewswire)
May-07-24 01:54PM	NMRA Stock Earnings: Neumora Therapeutics Meets EPS for Q1 2024 (InvestorPlace)
10:20AM	Neumora Therapeutics Shares Fall as Q1 Loss Narrows (MT Newswires)
07:00AM	Neumora Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
May-06-24 07:00AM	Neumora Therapeutics to Participate in Upcoming Conferences in May (GlobeNewswire)
Apr-16-24 11:28AM	Neumora (NMRA) Down on FDA Clinical Hold on Neurology Drug (Zacks)
Apr-15-24 04:20PM	Neumora Stock Hits 2024 Low As Side Effects In Rabbits Torpedo Schizophrenia Drug (Investor's Business Daily) -17.48%
12:17PM	Loading…
12:17PM	Why Is Neurology Focused-Neumora Therapeutics Shares Trading Lower On Monday? (Benzinga)
08:45AM	Why Is Neumora Therapeutics (NMRA) Stock Down 25% Today? (InvestorPlace)
07:47AM	Neumoras schizophrenia drug hit with clinical hold (BioPharma Dive)
06:36AM	U.S. FDA places clinical hold on Neumora's schizophrenia drug study (Reuters)
06:30AM	Neumora Therapeutics Announces Clinical Hold of Phase 1 NMRA-266 Study (GlobeNewswire)
Mar-13-24 07:00AM	Neumora Therapeutics to Participate at Stifel 2024 Virtual CNS Days (GlobeNewswire) -14.64%
Mar-07-24 02:52PM	NMRA Stock Earnings: Neumora Therapeutics Misses EPS for Q4 2023 (InvestorPlace)
07:00AM	Neumora Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Jan-22-24 07:00AM	Neumora Therapeutics Appoints Kaya Pai Panandiker as Chief Commercial Officer (GlobeNewswire) +9.89%
Jan-10-24 08:32AM	Why Neumora Therapeutics (NMRA) Stock Might be a Great Pick (Zacks)
Jan-02-24 07:00AM	Neumora Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-17-23 12:35PM	7 Stocks with Strong Insider Buying: December 2023 (InvestorPlace)
Dec-12-23 07:00AM	Neumora Therapeutics Appoints Jason Duncan as Chief Legal Officer (GlobeNewswire)
Nov-27-23 07:00AM	Neumora Therapeutics Announces NMRA-266 IND Clearance and Initiation of Phase 1 Clinical Study (GlobeNewswire)
Nov-01-23 07:00AM	Neumora Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Oct-30-23 07:00AM	Neumora Therapeutics to Participate in Upcoming Conferences in November (GlobeNewswire) -6.00%
Oct-10-23 07:00AM	Neumora Therapeutics Announces Appointment of Robert Lenz, M.D., Ph.D., as Executive Vice President, Head of Research and Development (GlobeNewswire) -6.45%
Sep-28-23 07:54PM	Ticking Time Bombs: 3 New Stocks to Dump Before the Damage Is Done (IPO) (InvestorPlace) +11.84% +6.73%
Sep-27-23 06:50PM	Tracking 2023's Largest IPOs: Instacart, Arm, Birkenstock and More (Updated November) (Observer)
Sep-18-23 12:35PM	UPDATE 3-Marketing firm Klaviyo lifts IPO price range, targets $9 bln valuation (Reuters) -8.92%
Sep-14-23 08:49PM	Neumora Therapeutics Announces Pricing of Initial Public Offering (GlobeNewswire)

Neumora Therapeutics, Inc. is a clinical-stage biotechnology company. It offers a precision medicine approach for brain diseases through the integration of data science and neuroscience. The firm focuses on advancing medicines for therapeutically relevant targets implicated in CNS diseases, targeting novel mechanisms of action with best-in-class pharmacology. The company was founded by Paul L. Berns, Carol Suh and Mike Poole in November 2019 and is headquartered in Watertown, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Fust Matthew K	Director	Oct 18 '24	Option Exercise	5.29	14,049	74,309	34,149	Oct 18 06:25 PM
Fust Matthew K	Director	Oct 17 '24	Option Exercise	6.81	7,739	52,730	27,839	Oct 18 06:25 PM
Fust Matthew K	Director	Oct 18 '24	Sale	17.03	14,049	239,319	20,100	Oct 18 06:25 PM
Fust Matthew K	Director	Oct 17 '24	Sale	17.01	7,739	131,643	20,100	Oct 18 06:25 PM
Fust Matthew K	Director	Oct 18 '24	Proposed Sale	17.03	14,049	239,319		Oct 18 04:01 PM
Fust Matthew K	Director	Oct 17 '24	Proposed Sale	17.01	7,739	131,643		Oct 17 04:26 PM
Lenz Robert A.	Head of R&D	Oct 10 '24	Sale	15.09	8,260	124,603	314,706	Oct 11 04:10 PM
Lenz Robert A.	Head of R&D	Oct 09 '24	Sale	15.01	5,563	83,507	322,966	Oct 11 04:10 PM
Lenz Robert A.	Officer	Oct 10 '24	Proposed Sale	15.09	8,260	124,603		Oct 10 04:30 PM
Lenz Robert A.	Officer	Oct 09 '24	Proposed Sale	15.01	5,563	83,507		Oct 09 04:10 PM
Lenz Robert A.	Head of R&D	Sep 17 '24	Sale	11.81	30,788	363,736	339,205	Sep 19 04:35 PM
Lenz Robert A.	Head of R&D	Sep 18 '24	Sale	12.09	10,676	129,091	328,529	Sep 19 04:35 PM
Lenz Robert A.	Officer	Sep 18 '24	Proposed Sale	12.09	10,676	129,091		Sep 18 04:27 PM
Lenz Robert A.	Officer	Sep 17 '24	Proposed Sale	11.81	30,788	363,734		Sep 17 04:37 PM
Lenz Robert A.	Head of R&D	Sep 12 '24	Sale	11.43	32,948	376,665	369,993	Sep 16 04:05 PM
Lenz Robert A.	Officer	Sep 12 '24	Proposed Sale	11.43	32,948	376,665		Sep 12 05:18 PM
Pinto Joshua	Chief Financial Officer	Aug 27 '24	Sale	11.39	15,693	178,806	138,965	Aug 27 05:58 PM
Pinto Joshua	Chief Financial Officer	Aug 26 '24	Sale	11.78	31,642	372,588	154,658	Aug 26 06:17 PM
Pinto Joshua	Chief Financial Officer	Aug 22 '24	Sale	11.63	28,496	331,468	210,469	Aug 26 06:17 PM
Pinto Joshua	Chief Financial Officer	Aug 23 '24	Sale	11.59	24,169	280,005	186,300	Aug 26 06:17 PM
Pinto Joshua	Officer	Aug 22 '24	Proposed Sale	11.90	100,000	1,190,000		Aug 22 09:48 AM

MTSR

Metsera Inc

PRME

Prime Medicine Inc

NMRA

Neumora Therapeutics Inc

Upgrade your FINVIZ experience